CJC-1295 + Ipamorelin
GHRH / GHRP Combination
A synergistic growth hormone releasing combination for body composition, sleep, and recovery.
- Increased lean muscle mass
- Reduced body fat
- Deeper, more restorative sleep
Tracks
Apple Health Outcome
10 compoundsin Regimen’s catalog are configured to track deep sleep via Apple Health. Each one shows the dose range, listed benefits, and every outcome it’s set up to monitor. Tap through to plan a dose with the free reconstitution calculator.
10 compounds
GHRH / GHRP Combination
A synergistic growth hormone releasing combination for body composition, sleep, and recovery.
Tracks
Tracks
Tracks
GHRH (1-29) Analog
Synthetic analog of the first 29 amino acids of growth hormone–releasing hormone. Stimulates the pituitary to release endogenous GH in pulses, preserving the natural feedback loop and avoiding suppressed pituitary axis seen with exogenous HGH.
Tracks
Recombinant Human Growth Hormone
Recombinant DNA-derived 191-amino-acid growth hormone identical to endogenous human somatropin. FDA-approved for clinical GH deficiency (adult and pediatric); used off-label for body composition, recovery, and anti-aging. Direct hormone replacement — bypasses the pituitary axis (unlike Sermorelin/Tesamorelin).
Tracks
Tracks
Tracks
Ghrelin Receptor GH Secretagogue
A synthetic hexapeptide that binds the ghrelin/GHS-R1a receptor to stimulate pulsatile growth hormone release from the anterior pituitary. Researched for GH deficiency, cachexia, and tissue-protective effects; also a potent appetite stimulant.
Tracks
Oral Ghrelin Mimetic / GH Secretagogue
An orally bioavailable, non-peptide ghrelin receptor agonist that produces sustained increases in GH and IGF-1 with once-daily dosing. Taken as a capsule — no reconstitution needed. Studied for sarcopenia, GH deficiency, and recovery support.
Tracks
Next-gen Ghrelin Receptor Agonist (research)
A research-grade non-peptide ghrelin receptor (GHS-R1a) agonist developed as a successor to MK-677. Vendor and analog modeling describe higher receptor affinity and longer half-life, but human clinical data are not yet published.
Tracks
Other outcomes